Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting
yahoo.com
news
2022-10-21 22:03:00

Highlights include an analysis of predictive biomarkers for overall survival and progression free survival in newly diagnosed glioblastoma patients

Pre-clinical research shows the potential for improved tumor control when Tumor Treating Fields are used with PULSAR in glioblastoma, PARP inhibitors in ovarian cancer and PI3K inhibitors in non-small cell lung cancer, GBM and ovarian cancer

ROOT, Switzerland, October 21, 2022--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced 11 poster presentations on Tumor Treating Fields (TTFields) will be featured at the American Society for Radiation Oncology (ASTRO) 2022 Annual Meeting from Oct.
